Curie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer
Curie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer

News & Media

The latest on Curie Therapeutics
Curie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer

CAMBRIDGE, Mass., February 7, 2022 — Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Bernard Lambert, Ph.D., as Chief Technology Officer. Dr. Lambert joins Curie Therapeutics to lead the Company’s process development, manufacturing, and technical operations.

“I believe that the future success for precision radiopharmaceuticals will be in rationally designed molecules and payloads that are optimized for the right target, in the right patient, and at the right dose,” said Dr. Lambert. “To execute on all of these aspects requires that a company be not only adept in ligand R&D but also capable of fully integrating radiochemistry, translational sciences and clinical development under one roof. Curie is one of the few companies committed to this approach and I am delighted to be joining the leadership team.”

“Bernard is recognized as a leading figure in the development of therapeutic and companion diagnostic radiopharmaceutical molecules. His technical depth in radiochemistry, general management experience, and track record in commercializing radiopharmaceuticals and global supply chains will be invaluable in this next phase of growth as we accelerate expansion of Curie’s platform and pipeline,” said Simon Read, Curie’s CEO and founder.

Dr. Lambert brings over 20 years of experience in radiopharmaceutical drug development, including leading commercial strategy and operations from IND through NDA and expertise in all phases of discovery and development, with commercial launches in oncology with both small molecules and antibody-based imaging programs.

Most recently, he served as president and chief operating officer of Telix Pharmaceuticals’ U.S. subsidiary, where he spearheaded development of its U.S. manufacturing infrastructure and led regulatory and commercial operations for both its clinical stage and marketed renal, prostate, and brain cancer theranostic product combinations. Prior to Telix, Dr. Lambert was vice president, CMC and Radiopharmaceutical Development at Zevacor Pharma and Zevacor Molecular and IBA Molecular, where he contributed to multiple first-in-human diagnostic and therapy programs. He received his Ph.D. in chemistry from the University of Liège.

About Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie’s mission is to revolutionize the use of radiomedicines in cancer. Learn more at www.curietherapeutics.com

Contacts
Argot Partners
Media: Sarah Sutton
IR: Kevin Murphy
curie@argotpartners.com
212.600.1902